• 1
    Löwenberg B. Acute myeloid leukemia: The challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program 2008; 111.
  • 2
    Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009; 385395.
  • 3
    Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937951.
  • 4
    Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111: 39413967.
  • 5
    Haycocks NG, Lawrence L, Cain JW, Zhao XF. Optimizing antibody panels for efficient and cost-effective flow cytometric diagnosis of acute leukemia. Cytometry B Clin Cytom 2011; 80: 221229.
  • 6
    Al-Mawali A, Gillis D, Hissaria P, Lewis I. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 2008; 129: 934945.
  • 7
    Olaru D, Campos L, Flandrin P, Nadal N, Duval A, Chautard S, Guyotat D. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes. Cytometry B Clin Cytom 2008; 74: 1724.
  • 8
    Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T, Kern W. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004; 62: 2538.
  • 9
    Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol 2011; 53: 421436.
  • 10
    Al-Mawali A, To L, Gillis D, Hissaria P, Mundy J, Lewis I. The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia. Int J Lab Hematol 2009; 31: 6168.
  • 11
    Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011; 0: 10091019.
  • 12
    Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 2542.
  • 13
    Marshall ASJ, Willment JA, Lin H-H, Williams DL, Gordon S, Brown GD. Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem 2004; 279: 1479214802.
  • 14
    Marshall ASJ, Willment JA, Pyz E, Dennehy KM, Reid DM, Dri P, Gordon S, Wong SYC, Brown GD. Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur J Immunol 2006; 36: 21592169.
  • 15
    van Rhenen A, Moshaver B, Ossenkoppele GJ, Schuurhuis GJ. New approaches for the detection of minimal residual disease in acute myeloid leukemia. Curr Hematol Malig Rep 2007; 2: 111118.
  • 16
    van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AWM, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007; 21: 17001707.
  • 17
    Becker MW, Jordan CT. Leukemia stem cells in 2010: Current understanding and future directions. Blood Rev 2011; 25: 7581.
  • 18
    van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, Broxterman HJ, Ossenkoppele GJ, Schuurhuis GJ. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003: 88; 983993.
  • 19
    Swerdlow HS. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer, World Health Organization; 2008. pp 439.
  • 20
    Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993; 100: 534540.
  • 21
    Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E, Reiffers J, Boisseau MR, Bernard P. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997; 11: 18781886.
  • 22
    Béné MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: A consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011; 25: 567574.
  • 23
    Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010; 115: 19761984.
  • 24
    Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19: 138152.
  • 25
    Tomová A, Babusíková O. Shifts in expression of immunological cell markers in relapsed acute leukemia. Neoplasma 2001; 48: 164168.
  • 26
    Vercauteren SM, Sutherland HJ. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 2001; 3: 449459.
  • 27
    Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U, Reinhardt D. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry B Clin Cytom 2005; 63: 19.
  • 28
    Li X, Du W, Liu W, Li X, Li H, Huang S-A. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. APMIS 2010; 118: 353359.
  • 29
    Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010; 23: 379390.
  • 30
    Al-Mawali A, Gillis D, Lewis I. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom 2009; 76: 91101.
  • 31
    Björklund E, Gruber A, Mazur J, Mårtensson A, Hansson M, Porwit A. CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients. Int J Hematol 2009; 90: 292302.
  • 32
    Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission: What is lacking before we can apply minimal residual disease as an integrated tool in clinical decision-making? Blood 2011; 117: 25772584.